Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 20/20 | 1.00 |
| ▸ | F10 | P00742 | 20/20 | 1.00 |
| ▸ | PLAU | P00749 | 1/20 | 1.00 |
| ▸ | HPN | P05981 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6437463 | 1.00 | F2 (1.00) | F2F10PLAUHPN | |
| SCHEMBL7426564 | 1.00 | F2 (1.00) | F2F10PLAUHPN | |
| SCHEMBL7444271 | 1.00 | F2 (1.00) | F2F10PLAUHPN | |
| SCHEMBL7438024 | 0.98 | F2 (1.00) | F2F10PLAUHPN | |
| Hydrochloric Acid SCHEMBL4904976 | 0.98 | F2 (0.97) | F2F10PLAUHPN | |
| SCHEMBL7442529 | 0.98 | F2 (1.00) | F2F10PLAUHPN | |
| Hydrochloric Acid SCHEMBL4904982 | 0.98 | F2 (0.97) | F2F10PLAUHPN | |
| SCHEMBL7435108 | 0.98 | F2 (1.00) | F2F10PLAUHPN | |
| SCHEMBL7433726 | 0.98 | F2 (1.00) | F2F10PLAUHPN | |
| Hydrochloric Acid SCHEMBL30566763 | 0.98 | F2 (0.97) | F2F10PLAUHPN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129547-B2 | Anticoagulation of human blood ex vivo | HELLSTERN PETER (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20100280412-A1 | Anticoagulation Of Human Blood Ex Vivo | HELLSTERN PETER | 2010-11-04 | — | — | US | disclosed |
| EP-1042287-B1 | INDOLE DERIVATIVES AS INHIBITORS OF FACTOR XA | AVENTIS PHARMA GMBH (DE) | 2005-04-20 | — | — | EP | disclosed |
| US-6759384-B1 | LOW MOLECULAR WEIGHT ANTICOAGULANTS WITHOUT SIDE EFFECTS; DERIVATIVES OF AT LEAST PROLINE, LEUCINE AND ARGININE SEQUENCE | AVENTIS PHARMACEUTICALS INC. | 2004-07-06 | — | — | US | disclosed |
| EP-0874629-B1 | ISOXAZOLINE, ISOTHIAZOLINE AND PYRAZOLINE FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-05-19 | — | — | EP | disclosed |
| EP-0758341-B1 | FACTOR Xa INHIBITORS | AVENTIS PHARMA INC (US) | 2004-03-24 | — | — | EP | disclosed |
| EP-1384725-A2 | Factor Xa inhibitors | Aventis Pharmaceuticals, Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-0892780-B1 | M-AMIDINO PHENYL ANALOGS AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-11-20 | — | — | EP | disclosed |
| US-6337344-B1 | ANTICOAGULANTS AND ENZYME INHIBITORS FOR CARDIOVASCULAR DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-01-08 | — | — | US | disclosed |
| EP-1042287-A1 | INDOLE DERIVATIVES AS INHIBITORS OF FACTOR XA | Aventis Pharma Deutschland GmbH (DE) | 2000-10-11 | — | — | EP | disclosed |
| US-5942544-A | α-branched anilines, toluenes, and analogs thereof as factor Xa inhibitors | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-08-24 | — | — | US | disclosed |
| US-5939418-A | ANTICOAGULANT | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1999-08-17 | — | — | US | disclosed |
| WO-1999033800-A1 | INDOLE DERIVATIVES AS INHIBITORS OR FACTOR XA | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-07-08 | — | — | WO | disclosed |
| US-5849510-A | Factor Xa inhibitors | SELECTIDE CORPORATION (US) | 1998-12-15 | — | — | US | disclosed |
| WO-1995029189-A1 | FACTOR Xa INHIBITORS | SELECTIDE CORPORATION (US) | 1995-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280412-A1 | Anticoagulation Of Human Blood Ex Vivo | F5, TFPI, F11 | F2 13/4885F10 9/4885PLAU 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.